Cargando…
Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers
A large number of potential tissue biomarkers has been proposed for brain tumors. However, hardly any have been adopted for routine clinical use, so far. For most candidate biomarkers substantial controversy exists with regard to their usefulness in clinical practice. The multidisciplinary neuroonco...
Autores principales: | Berghoff, Anna S., Stefanits, Harald, Woehrer, Adelheid, Heinzl, Harald, Preusser, Matthias, Hainfellner, Johannes A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663466/ https://www.ncbi.nlm.nih.gov/pubmed/23618424 http://dx.doi.org/10.5414/NP300646 |
Ejemplares similares
-
Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers
por: Berghoff, Anna Sophie, et al.
Publicado: (2012) -
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015) -
Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?
por: Woehrer, Adelheid, et al.
Publicado: (2013) -
Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
por: Berghoff, Anna S., et al.
Publicado: (2012) -
Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
por: Preusser, Matthias, et al.
Publicado: (2014)